This site is intended for healthcare professionals
Drug news

Nektar Therapeutics announces formation of Inheris Biopharma Inc., a CNS focused company

Read time: 1 mins
Last updated:24th May 2019
Published:24th May 2019
Source: Pharmawand

Nektar Therapeutics announced the formation of Inheris Biopharma, Inc., a wholly-owned subsidiary of Nektar and a CNS-focused company. Inheris will be responsible for launch preparation and commercialization for NKTR 181, a novel, first-in-class, investigational opioid molecule.

NKTR 181 is currently under review with the FDA, with a Prescription Drug User Fee Act (PDUFA) target action date of 29 August 2019. Inheris will also lead development of several Nektar preclinical CNS assets.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights